Catalyst Pharmaceutical Partners (CPRX) PT Lowered to $4.50 at Roth Capital
Roth Capital analyst Scott Henry lowered the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $4.50 (from $7.00) while maintaining a Buy rating.
Roth Capital analyst Scott Henry lowered the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $4.50 (from $7.00) while maintaining a Buy rating.